<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35584348</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2473-4284</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>JCO precision oncology</Title>
          <ISOAbbreviation>JCO Precis Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tumor and Constitutional Sequencing for Neurofibromatosis Type 1.</ArticleTitle>
        <Pagination>
          <StartPage>e2100540</StartPage>
          <MedlinePgn>e2100540</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/PO.21.00540</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE"><i>NF1</i> variants in tumors are important to recognize, as multiple mechanisms may give rise to biallelic variants. Both deletions and copy-neutral loss of heterozygosity (LOH) are potential mechanisms of <i>NF1</i> loss, distinct from point mutations, and additional genes altered may drive different tumor types. This study investigates whether tumors from individuals with neurofibromatosis type 1 (NF1) demonstrate additional gene variants and detects <i>NF1</i> second hits using paired germline and somatic sequencing. In addition, rare tumor types in NF1 may also be characterized by tumor sequencing.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Sequences of 529 cancer driver genes were analyzed in 6,381 tumors, yielding 391 <i>NF1</i>-mutated tumors in which <i>NF1</i> LOH analysis was performed. Driver genes were evaluated by tumor type including malignant peripheral nerve sheath tumors and gliomas.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS"><i>NF1</i> LOH was seen in 133 of 391 tumor samples in the cohort. Individuals with NF1 had more prevalent copy-neutral LOH (<i>P</i> &lt; .0001), suggesting somatic intrachromosomal recombination. Osteosarcoma in NF1 also had <i>NF1</i> LOH and additional p53 alteration. <i>NF1</i> second hit data from tumors were informative for inferring deleteriousness of missense variants that were conflicting in ClinVar, potentially helping to add to <i>NF1</i> annotation. Although criteria for evaluating germline and somatic variants are different, deleterious effects on <i>NF1</i> function may be shared.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Sequencing of NF1-associated tumors demonstrated a spectrum of second hits in <i>NF1</i> and the prevalence of copy-neutral LOH. Future work may be aimed at further understanding of LOH mechanisms and strategies to mitigate tumor risk.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tong</LastName>
            <ForeName>Schuyler</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, Pediatrics, Benioff Children's Hospital Oakland, University of California San Francisco, San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Devine</LastName>
            <ForeName>W Patrick</ForeName>
            <Initials>WP</Initials>
            <Identifier Source="ORCID">0000-0003-4634-8830</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of California San Francisco, San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shieh</LastName>
            <ForeName>Joseph T</ForeName>
            <Initials>JT</Initials>
            <Identifier Source="ORCID">0000-0003-0746-6084</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of California San Francisco, San Francisco, CA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Medical Genetics, Pediatrics, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>JCO Precis Oncol</MedlineTA>
        <NlmUniqueID>101705370</NlmUniqueID>
        <ISSNLinking>2473-4284</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019656" MajorTopicYN="N">Loss of Heterozygosity</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009456" MajorTopicYN="Y">Neurofibromatosis 1</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>16</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35584348</ArticleId>
        <ArticleId IdType="doi">10.1200/PO.21.00540</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
